ATE538782T1 - Modifizierte aminosaeure 5-cnac zur hemmung der thrombozytenaggregation - Google Patents

Modifizierte aminosaeure 5-cnac zur hemmung der thrombozytenaggregation

Info

Publication number
ATE538782T1
ATE538782T1 AT03763878T AT03763878T ATE538782T1 AT E538782 T1 ATE538782 T1 AT E538782T1 AT 03763878 T AT03763878 T AT 03763878T AT 03763878 T AT03763878 T AT 03763878T AT E538782 T1 ATE538782 T1 AT E538782T1
Authority
AT
Austria
Prior art keywords
modified amino
cnac
amino acids
thrombocyte aggregation
inhibiting
Prior art date
Application number
AT03763878T
Other languages
German (de)
English (en)
Inventor
Simon Bateman
Moise Azria
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE538782T1 publication Critical patent/ATE538782T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/23Calcitonins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727Heparin; Heparan
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/29Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
AT03763878T 2002-07-17 2003-07-16 Modifizierte aminosaeure 5-cnac zur hemmung der thrombozytenaggregation ATE538782T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39689802P 2002-07-17 2002-07-17
PCT/EP2003/007739 WO2004006907A1 (en) 2002-07-17 2003-07-16 Modified amino acid for the inhibition of platelet aggregation

Publications (1)

Publication Number Publication Date
ATE538782T1 true ATE538782T1 (de) 2012-01-15

Family

ID=30116066

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03763878T ATE538782T1 (de) 2002-07-17 2003-07-16 Modifizierte aminosaeure 5-cnac zur hemmung der thrombozytenaggregation

Country Status (12)

Country Link
US (3) US20060106110A1 (https=)
EP (1) EP1556027B1 (https=)
JP (1) JP4541884B2 (https=)
CN (1) CN1668290B (https=)
AT (1) ATE538782T1 (https=)
AU (1) AU2003257473A1 (https=)
BR (1) BR0312712A (https=)
CA (1) CA2492378C (https=)
ES (1) ES2379949T3 (https=)
PT (1) PT1556027E (https=)
TW (1) TW200403052A (https=)
WO (1) WO2004006907A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7318925B2 (en) 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone
WO2005016111A2 (en) 2003-08-08 2005-02-24 Abgenix, Inc. Antibodies directed to parathyroid hormone (pth) and uses thereof
JP5331476B2 (ja) 2005-06-15 2013-10-30 カリダ・ジェノミックス・インコーポレイテッド 遺伝子解析および化学解析用の単分子アレイ
PE20100241A1 (es) 2005-09-19 2010-04-16 Emisphere Tech Inc Formas cristalinas de la sal di-sodio del acido n-(5-clorosaliciloil)-8-aminocaprilico
CA2662853C (en) 2006-08-31 2016-07-26 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
AU2007289344B2 (en) * 2006-08-31 2011-04-14 Novartis Ag Pharmaceutical compositions comprising hGH for oral delivery
NZ585080A (en) 2007-11-02 2012-05-25 Emisphere Tech Inc Composition comprising Vitamin B12 and N-[8-(2-hydroxybenzoyl) amino ]caprylic acid and salts thereof for treating Vitamin B12 deficiency
CA2790708A1 (en) * 2010-02-24 2011-09-01 Emisphere Technologies, Inc. Oral b12 therapy
RU2504536C1 (ru) * 2012-08-20 2014-01-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Волгоградский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации Производное амида салициловой кислоты, обладающее антибактериальной, противогрибковой и антилизоцимной активностью

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260321A (en) * 1984-11-12 1993-11-09 Sandoz Ltd. Use of 1,4-dihydropyridine derivatives and combinations thereof with calcitonins
US5733647A (en) * 1992-11-05 1998-03-31 Polymer Innovations, Inc. Insole
US5563158A (en) * 1993-12-28 1996-10-08 The Dupont Merck Pharmaceutical Company Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists
BR9604880A (pt) * 1995-03-31 1998-05-19 Emisphere Tech Inc Composto composição forma de unidade de dosagem métodos para administração de um agente biologicamente ativo para preparar uma composição para administração de um agente ativo e para preparar um composto e composição farmacológica
US5866536A (en) * 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5773647A (en) * 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
CA2319680C (en) * 1997-02-07 2010-04-20 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
EP1175390B1 (en) * 1999-04-05 2005-02-02 Emisphere Technologies, Inc. Disodium salts, monohydrates, and ethanol solvates
US7049283B2 (en) * 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents

Also Published As

Publication number Publication date
US8664211B2 (en) 2014-03-04
PT1556027E (pt) 2012-04-10
CN1668290B (zh) 2010-04-28
JP4541884B2 (ja) 2010-09-08
US20080280817A1 (en) 2008-11-13
CA2492378C (en) 2011-06-14
CA2492378A1 (en) 2004-01-22
EP1556027A1 (en) 2005-07-27
US20060106110A1 (en) 2006-05-18
EP1556027B1 (en) 2011-12-28
US20120088833A1 (en) 2012-04-12
ES2379949T3 (es) 2012-05-07
BR0312712A (pt) 2005-04-26
AU2003257473A1 (en) 2004-02-02
WO2004006907A1 (en) 2004-01-22
JP2005535670A (ja) 2005-11-24
CN1668290A (zh) 2005-09-14
TW200403052A (en) 2004-03-01

Similar Documents

Publication Publication Date Title
EA200301165A1 (ru) Лекарственное средство на основе оксикодона
EP1614676A4 (en) CONNECTION TO INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICAMENT CONTAINING THEREOF
DK1135117T3 (da) Medikament til behandling af kronisk obstruktiv lungesygdom
GEP20074123B (en) Amino acids with affinity for the alpha−2−delta−protein
BR9510168A (pt) Composto poliaminoácido composição forma unitária de dosagem e método par epreparar uma composição
EA200700387A1 (ru) Гидраты и полиморфы 4-[[(7r)-8-циклопентил-7-этил-5,6,7,8-тетрагидро-5-метил-6-оксо-2-птеридинил]амино]-3-метокси-n-(1-метил-4-пиперидинил)бензамида, способы их получения и их применение в качестве лекарственных средств
PT1245568E (pt) Derivados sulfonilo de aminoacidos e sua utilizacao enquanto inibidores da dipeptidil-peptidase iv (dpp iv)
DE602005016532D1 (de) Pharmazeutische zusammensetzung mit einem benzodiaeins
SE0002202D0 (sv) New peptides
BR0207883A (pt) Composições de medicamentos à base de anticolenérgicos e inibidores de pde-iv
MXPA03000510A (es) Sales estables de acido o-acetilsalicilico con aminoacidos basicos.
EA200401227A1 (ru) Система доставки лекарства с контролируемым высвобождением, включающая правастатин
ATE538782T1 (de) Modifizierte aminosaeure 5-cnac zur hemmung der thrombozytenaggregation
ATE435657T1 (de) Therapeutische zubereitung von hochreinem fviia und verfahren zu dessen gewinnung
BRPI0410861A (pt) métodos e composições para a produção de aminoácidos
ATE402175T1 (de) 4-oxo-1-(3-substituiertesphenyl)-1,4-dihydro-1, - naphthyridin-3-carbonsäureamide alsphoshodiesterase-4-inhibitoren
DK0669912T3 (da) N-(3-Piperidinylcarbonyl)-beta-alaninderivater som PAF-antagonister
HRP20050371B1 (hr) Oblik za primjenu farmaceutiski djelatnih peptida s produljenim oslobađanjem djelatnog sastojka i postupak za njihovu proizvodnju
ES2422081T3 (es) Péptido Ser-Ser-Ser-Arg y sus utilizaciones medicinales
BR0009472A (pt) Antagonistas de lhrh com propriedades desolubilidade aperfeiçoadas
ID27818A (id) Metode untuk menyediakan glutamin
BR0311642A (pt) Formulação de divalproex de sódio de liberação aumentada
EA200401303A1 (ru) Лекарственные средства, содержащие стероиды и новое антихолинергическое средство
EP4566667A3 (en) Treatment of cardiometabolic disease with inhibitors of type i interferon signalling
EA200501557A1 (ru) Новый способ синтеза (2s)-индолин-2-карбоновой кислоты и использование в синтезе периндоприла